ASCO 2021 Conference Review focus on Melanoma

In this review:

CheckMate 067: 6.5-year outcomes in advanced melanoma
Relatlimab + nivolumab vs nivolumab in first-line advanced melanoma
Lifileucel for patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy
Three-year results of two dosing regimens of nivolumab + ipilimumab for advanced melanoma
Five-year OS of encorafenib + binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Lenvatinib + pembrolizumab for advanced melanoma and PD on a PD-1 or PD-L1 inhibitor
OS benefit from tebentafusp in patients with best response of PD
Final analysis of OS and RFS with high-dose interferon or ipilimumab vs pembrolizumab in patients with high-risk resected melanoma
Rechallenge with pembrolizumab in recurrent patients after complete resection of high-risk stage III melanoma Neoadjuvant and adjuvant nivolumab + relatlimab for resectable stage III melanoma

Please login below to download this issue (PDF)